Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

In this online program experts discuss how to best use BTK inhibitors to enhance patient care across multiple B-cell malignancies. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium in Orlando and read expert commentaries on the new data to learn more about how and when to use BTK-targeted regimens for your patients with cancer.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly